Core Viewpoint - The market is currently experiencing volatility in gold prices, with both bullish and bearish opportunities available as traders await the release of PCE data, which may influence gold's movement [1][3]. Gold Market Analysis - Gold has shown significant oscillation this week, lacking a clear trend, making it challenging for mid to long-term analysts to secure profits without risking losses [3]. - The recent trading day saw gold prices rise to around 3350 before falling to a low of 3310, indicating a lack of strong directional movement [4]. - The overall trend for gold remains bullish as long as it does not drop below 3280, with key resistance levels at 3355 and support levels at 3310 and 3295 [4][5]. Silver Market Analysis - Silver prices have not yet completed their upward movement, with expectations for further increases, particularly targeting around 37 [3][5]. - After a recent profit-taking at 35.2, silver has shown potential for further gains, with a current trading price around 36.7 and a target of 37 for potential short positions [5][6]. Domestic Market Insights - Domestic gold prices have remained stable, with expectations for upward movement, particularly for Shanghai gold, which is projected to reach around 795 [5]. - The domestic silver market has also shown positive movement, with recent trades indicating a bullish trend as long as support at 35.2 holds [5][6]. Oil Market Overview - International crude oil has shown limited movement, maintaining a bullish trend with support at 64, but future price movements will depend on market news and developments [6]. - Domestic fuel oil has experienced adjustments but is still viewed as bullish in the long term, with potential targets of 3000 to 3200 [7].

证券代码：300109 证券简称：新开源 公告编号：2025-026 公司董事赵威先生收到中国证券监督管理委员会（以下简称"中国证监会"）的《立 案告知书》（编号：证监立案字0122025004号），根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，中国证监会决定对赵威先生因涉嫌 短线交易予以立案。 告知书》（〔2025〕1号），具体内容详见公司于2025年4月3日披露的《关于公 司董事收到行政处罚事先告知书的公告》（公告编号：2025-005）。 公司近日收到赵威先生的通知，获悉其已收到中国证监会河南监管局下发的 《行政处罚决定书》（〔2025〕2号）（以下简称《决定书》），现将相关情况 公告如下： 一、《行政处罚事决定书》主要内容 当事人:赵威，男，1965年5月出生，博爱新开源医疗科技集团股份有限公司 (以下简称新开源)董事，住址:辽宁省抚顺市新抚区。 依据《中华人民共和国证券法》(以下简称《证券法》)有关规定，我局对赵 威短线交易新开源股票案进行了立案调查，依法向当事人告知了作出行政处罚的 事实、理由、依据及当事人依法享有的权利，当事人未提出陈述、申辩意见，也 未要求听证。本案现已 ...

黄金日内反弹遇阻，CPI数据公布前，短线交易者留意这几处关键位。立即观看超V研究员Cici的分析， 马上进入直播间>>> 相关链接 ...

Core Insights - The article explores the lives and strategies of some of the most famous futures traders, highlighting their innovative methods, risk management techniques, and discipline, which provide valuable lessons for traders and investors [1][13]. Group 1: Richard Dennis - Richard Dennis, known as the "King of Trading," turned a small loan into over $200 million by his early 30s and is famous for the "Turtle Traders" experiment, proving that trading can be taught [2][4]. - His breakout strategy involves buying when prices break above a certain level and selling when they fall below, based on the assumption that trends tend to continue [4]. - Dennis emphasizes strict risk management, typically risking only 1-2% of his capital on any single trade, which helps him survive consecutive losses [4]. - He adjusts position sizes based on market volatility, increasing positions in low-volatility markets and decreasing them in high-volatility ones [4]. - Quick stop-loss orders are a key rule for Dennis, ensuring that losses are kept to a minimum [4]. Group 2: Paul Tudor Jones - Paul Tudor Jones, founder of Tudor Investment Corp, is renowned for predicting and profiting from the 1987 stock market crash, reportedly tripling his funds that day [2][6]. - His global macro trading strategy involves making large bets across multiple asset classes based on macroeconomic trends, including futures [6]. - Jones values technical analysis alongside macroeconomic analysis, looking for chart patterns and signals for entry and exit points [6]. - He often takes contrarian positions, betting against prevailing market sentiment, believing that the best investment opportunities arise when market consensus is wrong [6]. - Dynamic risk management is central to his strategy, involving strict stop-losses and adjusting position sizes based on market volatility and confidence in trades [6]. Group 3: John W. Henry - John W. Henry, a legendary futures trader and owner of the Boston Red Sox and Liverpool FC, is known for his systematic, algorithm-driven trading approach [3][8]. - His trading strategy is based on systematic trend following, focusing on a wide range of futures markets to diversify risk and capture various market trends [8]. - Henry implements strict risk management rules, including capital allocation limits per trade and using stop-loss orders to protect against significant losses [8]. - He adopts a long-term perspective, willing to hold positions through drawdowns, believing in the long-term profitability of his strategies [8]. - Continuous research and development are crucial to his success, as he adapts his trading systems based on historical data and market behavior [8]. Group 4: Ed Seykota - Ed Seykota, an influential futures trader, is recognized for developing and implementing computerized trading systems in the 1970s [3][10]. - His strategy combines systematic trend following with emotional discipline, using automated systems to generate trading signals based on technical indicators and historical data [10]. - Seykota emphasizes the importance of position management in risk control, adjusting trade sizes based on market volatility to prevent significant damage to the overall portfolio [10]. - He is known for his focus on trading psychology, stressing the need to manage emotions and adhere to trading systems even during losing periods [10]. - Quick stop-loss orders are central to Seykota's strategy, allowing for rapid exits from losing trades to prevent small losses from escalating [10]. Group 5: Larry Williams - Larry Williams, a renowned commodity and futures trader, is famous for his short-term trading strategies and winning multiple trading competitions [3][12]. - His strategy focuses on short-term trading and precise market timing, particularly in commodity futures [12]. - Williams utilizes seasonal patterns in commodities as part of his trading approach [12]. - He emphasizes risk control, likening traders to warriors who need shields to protect themselves from losses, advocating for strong capital management [12]. - Williams believes that trading strategies should be personalized, akin to finding the right pair of shoes that fit well, rather than adhering to universally accepted methods [12].

策略师：关税问题反转是常态 短线交易难赚钱 金十数据5月30日讯，Ingalls & Snyder高级投资组合策略师Tim Ghriskey置评特朗普关税暂时恢复：市场 对关税问题已经麻木了，因为每天都有新消息新变化。现在我们又回到了特朗普掌权的时代。目前有很 多国家正在与美国进行贸易和关税谈判，时间框架很短。市场正在等待最终的解决方案，这可能对美国 整体有利，但可能不会与所有国家都成功达成协议。交易者会对这样的消息尽快做出反应，希望能获得 一点优势。但在股市上，快速交易并不能创造财富，财富是通过投资公司获得的……每天的变动只是沧 海一粟。正如我们所看到的，法院的裁决是相反的，所以作为交易者很难占据任何先机。而特朗普总统 又连续几天发表完全相反的声明，要么征收高额关税，要么取消关税。 ...

近日，冠城新材实际控制人之一薛黎曦收到江西证监局《行政处罚事先告知书》，拟被处以180万元罚 款。该告知书显示，薛黎曦因在2024年2月期间为稳定股价而建议他人买卖股票，以及利用其实际控制 的证券账户在买入后六个月内卖出冠城大通股票的行为，分别违反了《证券法》相关规定。 薛黎曦在冠城新材中扮演重要角色，持有丰榕投资68.54%股权，是该公司的法人代表。公开资料显 示，薛黎曦为冠城新材另一位实际控制人韩国龙的大儿媳，自2006年6月起担任冠城新材董事，同时也 是冠城钟表珠宝集团有限公司执行董事。 这已非薛黎曦首次受到监管处罚。此前在2023年12月，她曾因出席披露半年报期间的董事会会议但未提 交表决票被上交所监管警示。冠城新材近年来积极转型，剥离房地产业务，但业绩表现不佳，2023年以 来持续亏损。 本文源自：金融界 江西证监局经调查后拟对薛黎曦作出两项处罚决定：对其建议他人买卖冠城大通的行为处以150万元罚 款；对其短线交易冠城大通的行为给予警告并处以30万元罚款。薛黎曦在被调查后表现出认错态度，具 有主观恶性较小、配合调查等情节。 薛黎曦作为冠城新材实际控制人之一，同时担任公司董事。公司公告表示，此事仅涉及 ...

Core Viewpoint - The chairman and general manager of Maiwei Biotech, Liu Datao, has been placed under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, which raises concerns about the company's governance and its upcoming IPO in Hong Kong [1][5][6]. Company Overview - Maiwei Biotech is an innovative pharmaceutical company that has not yet achieved profitability, despite having three products on the market. The company has reported significant cumulative losses due to high research and development costs [4][5]. - As of the end of Q1 2023, Liu Datao held 15.1 million shares, representing 3.78% of the total share capital, making him the third-largest shareholder [3]. Financial Performance - The company reported revenues of approximately 44.79 million yuan in Q1 2023, a year-on-year decline of 33.7%. The corresponding net loss was about 292 million yuan, indicating an increase in losses compared to the previous year [5]. - Financial data for 2022-2024 shows revenues of approximately 27.73 million yuan, 128 million yuan, and 200 million yuan, with net losses of approximately 955 million yuan, 1.053 billion yuan, and 1.044 billion yuan respectively [3][4]. IPO Plans - Maiwei Biotech is planning to issue shares (H-shares) and list on the Hong Kong Stock Exchange to meet its funding needs for sustainable development and enhance its international profile. The company submitted its IPO application earlier this year [5]. - The investigation of the chairman may impact the IPO process, as regulatory bodies may extend the inquiry period and require additional information regarding the company's governance and internal controls [6].

Core Viewpoint - The article discusses the investigation of Liu Datao, the chairman and general manager of Maiwei Biotech, by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, which raises concerns about management stability and internal control effectiveness during a critical period for the company's H-share listing [1][4]. Company Overview - Maiwei Biotech is an innovative biopharmaceutical company with a full industry chain layout, focusing on the research, production, and sales of innovative drugs and biosimilars, including antibodies, ADC drugs, and recombinant proteins [3]. - The company has launched three products and is gradually increasing sales, but it has not achieved profitability since its establishment in 2017, accumulating losses of nearly 6 billion yuan [3][13]. Financial Performance - The company's revenue for 2022, 2023, and 2024 was 27.73 million yuan, 128 million yuan, and 200 million yuan, respectively, with year-on-year growth rates of 70.88%, 361.03%, and 56.28% [12]. - However, in the first quarter of 2024, revenue decreased to 45 million yuan, a year-on-year decline of 33.70%, with a net loss of 292 million yuan, down 41.85% year-on-year [12]. - Cumulative losses from 2022 to 2024 were 955 million yuan, 1.053 billion yuan, and 1.044 billion yuan, respectively, with total losses exceeding 3 billion yuan since the company went public [13]. Management and Governance - Liu Datao, the chairman, holds 3.78% of the company's shares and received a pre-tax remuneration of 2.7047 million yuan in 2024 [6]. - The actual controllers of the company are Tang Chunshan and Chen Shanna, holding 42.38% of the voting rights [8]. Regulatory Environment - The CSRC's investigation into Liu Datao for short-term trading could lead to increased scrutiny of the company's management and internal controls, especially as it approaches its H-share listing [4][16]. - Short-term trading by executives can undermine investor trust and disrupt market fairness, as these individuals have access to more internal information [8][9]. Future Prospects - Maiwei Biotech is actively seeking to meet its funding needs and enhance its internationalization by applying for a dual listing on the Hong Kong Stock Exchange [14]. - The company is also exploring financing options, including a proposed issuance of up to 500 million yuan in debt financing tools to optimize its debt structure and reduce financial costs [14].

黄金行情讲解中 黄金急转直下！市场炒作回归美联储政策？短线交易者应该回调布局还是谨慎等待？TTPS交易学长正 在直播分析中，点击马上观看！ 相关链接 ...

黄金欧盘反弹无力，短线能否追空入场？立即观看超V 研究员 Alex多品种实时分析>>> 相关链接 ...